In summary, although HDAC and HAT inhibitors present promising avenues for ischemic stroke therapy, substantial challenges related to selectivity, delivery, pharmacokinetics, and toxicity must be addressed. The gene discussed is TMPRSS11D; the disease is ischemic stroke.